PROLOR Biotech to Present at ILSI-Biomed 2011 Conference

NES-ZIONA, Israel, May 20, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that Dr. Abraham Havron, CEO of PROLOR, will give a corporate presentation at the ILSI-Biomed 2011 Conference.  The conference will be held at the David InterContinental hotel in Tel Aviv, Israel.

The PROLOR corporate presentation is scheduled for May 25, 2011 at 11:20 AM IDT.  

For more information on the conference, visit www2.kenes.com/biomed/pages/home.aspx.

ABOUT ILSI-Biomed

The ILSI-Biomed conference is the annual showcase of the Israeli Bio sector, which has one of the world's highest rates of patent filings and start-ups.  This vibrant industry is a model of creativity, productivity and efficiency, and the conference is attracting more foreign attendees who want to learn from its successes.  The ILSI-Biomed 2011 follows the success of previous annual conferences--last year's event drew 6,000 industry players, engineers and scientists, with 1,000 participants from 42 countries and in excess of 2,500 one-on-one meetings.

ABOUT PROLOR BIOTECH

PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology and its Reversible Pegylation technology, primarily to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins and the Reversible Pegylation technology is well-suited for use with peptides and small molecule therapeutics.  PROLOR is currently developing long-acting versions of human growth hormone, which is in Phase II clinical development, and Factor IX, Factor VII, and interferon beta, which are in preclinical development, as well as an anti-obesity peptide and agents for atherosclerosis and rheumatoid arthritis.  For more information, visit www.prolor-biotech.com.

PROLOR CONTACT:

MEDIA CONTACT:

Shai Novik, President

Barbara Lindheim

PROLOR Biotech, Inc.

GendeLLindheim BioCom Partners

Tel: +1 866 644-7811

+1 212 918-4650

Email: [email protected]

[email protected]



SOURCE PROLOR Biotech, Inc.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.